Suppr超能文献

早期乳腺癌中Oncotype DX复发评分与经典危险因素的相关性:土耳其一项前瞻性多中心研究的结果

Correlations Between Oncotype DX Recurrence Score and Classic Risk Factors in Early Breast Cancer: Results of A Prospective Multicenter Study in Turkey.

作者信息

Özmen Vahit, Atasoy Ajlan, Gökmen Erhan, Özdoğan Mustafa, Güler Nilufer, Uras Cihan, Ok Engin, Demircan Orhan, Işıkkdoğan Abdurrahman, Cabioğlu Neslihan, Şen Fatma, Saip Pınar

机构信息

Department of General Surgery, İstanbul University İstanbul School of Medicine, İstanbul, Turkey.

Division of Medical Oncology, Department of Internal Medicine, Marmara University School of Medicine, İstanbul, Turkey.

出版信息

J Breast Health. 2016 Jul 1;12(3):107-111. doi: 10.5152/tjbh.2016.2874. eCollection 2016 Jul.

Abstract

OBJECTIVE

Breast cancer is the most common malignancy among Turkish women and the rate of early stage disease is increasing. The Oncotype DX 21-gene assay is predictive of distant recurrence in ER-positive, HER2-negative early breast cancer. We aimed to evaluate the correlations between Recurrence Score (RS) and routine risk factors.

MATERIALS AND METHODS

Ten academic centers across Turkey participated in this prospective trial. Consecutive patients with breast cancer who had pT1-3, pN0-N1mic, ER-positive, and HER2-negative tumors were identified at tumor conferences. Both pre- and post-RS treatment decisions and physician perceptions were recorded on questionnaire forms. Correlations between RS and classic risk factors were evaluated using univariate and multivariate analyses.

RESULTS

Ten centers enrolled a total of 165 patients. The median tumor size was 2 cm. Of the 165 patients, 57% had low RS, 35% had intermediate RS, and 8% had high RS, respectively. Multivariate analysis indicated that progesterone receptor (PR) and Ki67 scores were significantly related to RS.

CONCLUSION

Oncotype DX Recurrence Score does not seem to have a significant correlation with the majority of classic risk factors, but it may have a correlation with PR score and Ki67 score.

摘要

目的

乳腺癌是土耳其女性中最常见的恶性肿瘤,且早期疾病的发生率正在上升。Oncotype DX 21基因检测可预测雌激素受体(ER)阳性、人表皮生长因子受体2(HER2)阴性早期乳腺癌的远处复发。我们旨在评估复发评分(RS)与常规风险因素之间的相关性。

材料与方法

土耳其的10个学术中心参与了这项前瞻性试验。在肿瘤会议上确定了连续的乳腺癌患者,这些患者的肿瘤为pT1-3、pN0-N1mic、ER阳性且HER2阴性。RS治疗前后的决策以及医生的看法都记录在问卷表上。使用单变量和多变量分析评估RS与经典风险因素之间的相关性。

结果

10个中心共纳入165例患者。肿瘤大小中位数为2厘米。在这165例患者中,分别有57%的患者RS较低,35%的患者RS中等,8%的患者RS较高。多变量分析表明,孕激素受体(PR)和Ki67评分与RS显著相关。

结论

Oncotype DX复发评分似乎与大多数经典风险因素没有显著相关性,但可能与PR评分和Ki67评分相关。

相似文献

5
Association between partial-volume corrected SUVmax and Oncotype DX recurrence score in early-stage, ER-positive/HER2-negative invasive breast cancer.
Eur J Nucl Med Mol Imaging. 2016 Aug;43(9):1574-84. doi: 10.1007/s00259-016-3418-1. Epub 2016 May 21.
6
Relevance of progesterone receptor immunohistochemical staining to Oncotype DX recurrence score.
Hematol Oncol Stem Cell Ther. 2016 Jun;9(2):48-54. doi: 10.1016/j.hemonc.2015.12.001. Epub 2016 Jan 18.
8
Routine pathologic parameters can predict Oncotype DX recurrence scores in subsets of ER positive patients: who does not always need testing?
Breast Cancer Res Treat. 2012 Jan;131(2):413-24. doi: 10.1007/s10549-011-1416-3. Epub 2011 Mar 3.
9
The Oncotype Dx Assay in ER-Positive, HER2-Negative Breast Cancer Patients: A Real Life Experience from a Single Cancer Center.
Eur J Breast Health. 2019 Jul 1;15(3):163-170. doi: 10.5152/ejbh.2019.4901. eCollection 2019 Jul.
10
Evaluation oncotype DX 21-gene recurrence score and clinicopathological parameters: a single institutional experience.
Histopathology. 2023 Apr;82(5):755-766. doi: 10.1111/his.14863. Epub 2023 Feb 1.

引用本文的文献

1
Assessment High-Risk Breast Cancer in Older Patients: A Comparative Analysis of PREDICT Scores and TAILORx Risk Categorization.
Eur J Breast Health. 2023 Oct 1;19(4):325-330. doi: 10.4274/ejbh.galenos.2023.2023-8-5. eCollection 2023 Oct.
2
MCM-2 Levels as a Potential Biomarker for Predicting High-Risk Breast Cancer Patients According to TAILORx Classification.
Breast Cancer (Dove Med Press). 2023 Sep 1;15:659-669. doi: 10.2147/BCTT.S421535. eCollection 2023.
6
BCL-2 expression aids in the immunohistochemical prediction of the Oncotype DX breast cancer recurrence score.
BMC Clin Pathol. 2018 Dec 18;18:14. doi: 10.1186/s12907-018-0082-3. eCollection 2018.
7
Gene Expression Profiling in Breast Cancer and Its Effect on Therapy Selection in Early-Stage Breast Cancer.
Eur J Breast Health. 2017 Oct 1;13(4):168-174. doi: 10.5152/ejbh.2017.3636. eCollection 2017 Oct.

本文引用的文献

1
Breast Cancer in Turkey: Clinical and Histopathological Characteristics (Analysis of 13.240 Patients).
J Breast Health. 2014 Apr 1;10(2):98-105. doi: 10.5152/tjbh.2014.1988. eCollection 2014 Apr.
3
Prospective Validation of a 21-Gene Expression Assay in Breast Cancer.
N Engl J Med. 2015 Nov 19;373(21):2005-14. doi: 10.1056/NEJMoa1510764. Epub 2015 Sep 27.
5
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Ann Oncol. 2013 Oct;24 Suppl 6:vi7-23. doi: 10.1093/annonc/mdt284. Epub 2013 Aug 22.
7
Prediction of the Oncotype DX recurrence score: use of pathology-generated equations derived by linear regression analysis.
Mod Pathol. 2013 May;26(5):658-64. doi: 10.1038/modpathol.2013.36. Epub 2013 Mar 15.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验